10-Q: Curis Reports Q1 2026 Results Amidst Going Concern Uncertainty

Curis, Inc. files its Q1 2026 10-Q, detailing ongoing development of emavusertib, significant net loss, and substantial doubt about its ability to continue as a going concern.

Summary

• Curis, Inc. reported its first-quarter 2026 financial results, highlighting continued development of its lead drug candidate, emavusertib.
• The company incurred a net loss of $24.2 million for the three months ended March 31, 2026, compared to a net loss of $10.6 million for the same period in 2025.
• Cash and cash equivalents stood at $15.0 million as of March 31, 2026, which is not expected to fund operations beyond 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• Research and development expenses decreased by 24% to $6.4 million, primarily due to lower employee-related and manufacturing costs.
• General and administrative expenses increased by 27% to $5.1 million, largely due to expenses related to the January 2026 PIPE Financing.
• The company is actively pursuing additional funding through various avenues, including equity financings and strategic transactions.
• Curis is focused on advancing emavusertib in clinical trials for hematological malignancies, including PCNSL and CLL.
• The company received a delisting determination letter from Nasdaq but has requested a hearing, which stayed further delisting actions.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the significant increase in net loss, the explicit statement of substantial doubt about the company's ability to continue as a going concern, and the ongoing Nasdaq delisting concerns.

Positives

• The company's lead drug candidate, emavusertib, has received Orphan Drug Designation from the FDA and European Commission for PCNSL, AML, and MDS.
• Progress in clinical trials for emavusertib, with meetings held with CHMP and FDA regarding potential accelerated regulatory paths.
• Successful completion of the January 2026 PIPE Financing, raising approximately $18.6 million in net proceeds.
• Regained compliance with Nasdaq's MVLS Rule on February 3, 2026, though still subject to monitoring.
• Cash and cash equivalents increased to $15.0 million from $5.1 million at the end of 2025.

Negatives

• Incurred a net loss of $24.2 million for Q1 2026, an increase from $10.6 million in Q1 2025.
• Substantial doubt exists regarding the company's ability to continue as a going concern due to recurring losses and insufficient cash to fund operations beyond 12 months.
• The company is not in compliance with Nasdaq's minimum bid price requirement and received a delisting determination letter.
• No revenues were generated in Q1 2026, and the company does not expect to generate revenues for several years.
• Significant increase in 'Other expense' to $12.7 million, primarily due to changes in the fair value of warrant liabilities.

Risks

• The company's dependence on the success of emavusertib, which is still in early clinical development, and the risk that clinical trials may not be successful.
• Substantial doubt about the company's ability to continue as a going concern due to significant losses and the need for substantial additional capital.
• The possibility of being unable to obtain or experiencing delays in obtaining marketing approval for emavusertib or any future drug candidates.
• Failure to regain and maintain compliance with Nasdaq's listing requirements, leading to potential delisting.
• Intense competition within the biotechnology sector, with competitors potentially developing or commercializing drugs more successfully.
• The company's reliance on third parties for clinical trials, and the risk of inadequate performance by these parties.
• The uncertainty and expense associated with the marketing approval process for drug candidates.
• Potential inability to obtain and maintain patent protection for its technologies and drugs.

Future Outlook

The company expects to continue generating operating losses in the foreseeable future and requires substantial additional capital to fund its research and development program, particularly for emavusertib, and to support ongoing operations. The company plans to seek additional funding through private or public equity financings, collaborations, or other strategic transactions. The success of emavusertib's development and commercialization is a key driver for future results.

Management Comments

• The company has concluded that conditions and events, considered in the aggregate, raise substantial doubt about its ability to continue as a going concern within one year after the date the financial statements are issued.
• The company plans to seek additional funding through a number of potential avenues, including private or public equity financings, exercise of outstanding warrants, collaborations, or other strategic transactions.
• If necessary funds are not available, the company will have to delay, reduce the scope of, or eliminate its development of emavusertib, potentially delaying the time to market for or preventing the marketing of emavusertib, which would have a material adverse effect on the company's operations and future prospects.
• The company has faced and expects to continue to face substantial difficulties in raising capital.
• The company is focusing its operations on its ongoing combination Phase 1/2 study in relapsed/refractory PCNSL with ibrutinib and its recently initiated Phase 2 combination study of emavusertib in CLL with zanubrutinib.

Industry Context

StockSavvy.ai notes that Curis's Q1 2026 filing reflects the high-risk, high-reward nature of early-stage biotechnology companies. The significant net loss and going concern warning are common for companies investing heavily in R&D without current revenue streams. The focus on emavusertib and its potential regulatory pathways aligns with industry trends of seeking accelerated approvals for rare diseases or unmet medical needs.

Comparison to Industry Standards

• Biotechnology companies in early-stage development often report substantial net losses and negative cash flows from operations, similar to Curis's reported $24.2 million net loss and $9.0 million cash used in operations for Q1 2026.
• The need for continuous capital raises is a standard characteristic of the sector. Curis's history of equity financings (October 2024, March 2025, July 2025, January 2026 PIPE Financing) is consistent with industry practices to fund lengthy and expensive drug development cycles.
• The pursuit of Orphan Drug Designation, as seen with emavusertib, is a common strategy in the industry to gain market exclusivity and potential regulatory advantages for treatments of rare diseases, mirroring efforts by companies like Sarepta Therapeutics or BioMarin Pharmaceutical.
• The Nasdaq listing concerns faced by Curis are not unique; many smaller biotech firms struggle with maintaining minimum bid prices and market capitalization requirements, sometimes leading to transfers to over-the-counter markets or delisting, a challenge also faced by companies like MannKind Corporation in its earlier stages.

Corporate Governance

Legal Proceedings

• The company is not in compliance with the requirements for continued listing on the Nasdaq Capital Market and received a delisting determination letter, though a hearing has been requested to stay delisting actions.

Stakeholder Impact

• Shareholders: Potential dilution from future equity financings, risk of delisting impacting stock liquidity and value, and uncertainty regarding the company's going concern status.
• Employees: Potential impact on stock-based compensation if stock price declines or delisting occurs; continued employment depends on the company's ability to secure funding and advance its drug development.
• Creditors/Suppliers: The going concern uncertainty may lead to increased scrutiny of payment terms and potential delays in payments.
• Collaborators (e.g., Aurigene): Continued collaboration is dependent on Curis's ability to fund its obligations and advance development programs.

Next Steps

• Continue clinical trials for emavusertib in PCNSL and CLL.
• Seek additional financing through equity financings, collaborations, or strategic transactions.
• Address Nasdaq delisting concerns by requesting a hearing and aiming to regain compliance with listing rules.
• Potentially advance emavusertib development in AML if additional funding is secured.
• Announce initial data from the TakeAim CLL study by December 2026.

Key Dates

Recommendation

While Curis is advancing its lead candidate emavusertib and has secured some financing, the significant increase in net loss, the explicit going concern warning, and the Nasdaq delisting risk present substantial headwinds. The company's future is heavily dependent on its ability to secure further funding and achieve positive clinical trial results. For existing investors, holding may be prudent given the potential upside if emavusertib is successful, but the risks warrant caution. New investors should approach with extreme caution due to the high risk profile.

Keywords

Curis, emavusertib, biotechnology, oncology, clinical trials, FDA, Nasdaq, going concern, drug development, hematological malignancies